: By acquiring GW, Jazz Pharmaceuticals significantly reduced its reliance on its flagship narcolepsy drug, Xyrem . The combined company now has a robust portfolio across neuroscience and oncology.
If you are looking to buy stock in , it is important to know that as of April 28, 2026, the company no longer trades under its own ticker symbol. It was fully acquired by Jazz Pharmaceuticals in May 2021 for approximately $7.2 billion. buy stock in gw pharmaceuticals
: Epidiolex was the first FDA-approved plant-derived cannabinoid medicine, used to treat severe forms of childhood-onset epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. It reached over $500 million in annual net sales in 2020 and has continued to expand globally as Epidyolex in Europe. It was fully acquired by Jazz Pharmaceuticals in
Investment Rationale for GW Pharmaceuticals (via Jazz Pharmaceuticals) : By acquiring GW